CXCR2 antagonist / Amgen - LARVOL DELTA

Targeting Chemokine Receptors CCR6 and CXCR2 in A Murine Model Of IL-36a-Induced Pustular Psoriasis (AAI 2019) - "Several types of psoriasiform dermatitis are associated with increased IL-36 cytokine activity in the skin...We found that the orally bioavailable small molecule CCR6/CXCR2 antagonist CCX624 did indeed reverse inflammatory cell accumulation in skin, as well as decrease total skin thickness and epidermal thickness...CCX624 treatment was more effective than saturating doses of anti-TNFα or anti-IL17RA, which are used in the clinic for treating GPP as first or second line treatments (respectively). These findings put CCR6 and CXCR2 forward as novel targets for a mechanistically distinct therapeutic approach for inflammatory skin diseases involving dysregulated IL-36 signaling, such as GPP"

Preclinical

Targeting chemokine receptors CCR6 and CXCR2 in a murine model of IL-36α-induced pustular psoriasis. (SID 2019) - "We found that the orally bioavailable small molecule CCR6/CXCR2 antagonist CCX624 did indeed reverse inflammatory cell accumulation in skin, as well as decreasing skin thickness and epidermal thickness. CCX624 treatment was more effective than saturating doses of anti-TNFα or anti-IL17RA, which are used in the clinic for treating GPP as first or second line treatments (respectively). These findings put CCR6 and CXCR2 forward as novel targets for a mechanistically distinct therapeutic approach for inflammatory skin diseases involving dysregulated IL-36 signaling, such as GPP."

Preclinical